Abstract: The present invention concerns sustained release sufentanil compositions for intramuscular administration, the preparation of said compositions and the use of said compositions for inhibiting pain, in particular post-operative pain, in animals, particularly in companion animals.

Abstract: The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising:(1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and(2) a pharmaceutically acceptable carrier;wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.

Abstract: The present invention relates to a composition comprising an antimigraine compound of formula (I) and chitosan, which is particularly suited for intranasal administration. ##STR1## Process for preparing said composition, its use as a medicine and a nasal spray device, especially a unidose nasal spray device containing said composition.

Abstract: The present invention relates to the use of a cyclodextrin or a derivative thereof as a mucoadhesive in an emulsion or aqueous solution, said cyclodextrin or derivative thereof being used in an amount from 10% to 70% by weight based on the total weight of the composition.

Abstract: A solution is disclosed for intravenous administration containing lubeluzole or a pharmaceutically acceptable addition salt thereof, an isotonizing agent, water and acid and base substances to adjust the pH of the solution in the range from 2.5 to 3.6.

Abstract: The present invention concerns a formulation for oral administration comprising an antifungal, a sufficient amount of a cyclodextrin or a derivative thereof, an aqueous acidic medium as bulk liquid carrier and an alcoholic co-solvent Addition of one or more pharmaceutically acceptable sweeteners and one or more pharmaceutically acceptable flavors thereto yields palatable oral formulations. A process of preparing such formulations and pharmaceutical dosage forms comprising said formulations.

Abstract: An aqueous suspension for oral administration comprising sabeluzole and a pharmaceutically acceptable carrier, having a pH in the range from 8 to 10; processes for preparing the same.

Abstract: The present invention relates to a topical oil-in-water emulsion composition comprising ketoconazole, an acetonide glucocorticosteroid and a dermatologically acceptable carrier, characterized by a pH above 2.5 and below 6, and a method of preparing said composition.